Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression

Genes and Development

Volumn 24, Issue 5, 2010, Pages 455-469

  Yamaguchi, Teppei ^a,b   Cubizolles, Fabien ^a   Zhang, Yu ^a,c   Reichert, Nina ^a   Kohler, Hubertus ^a   Seiser, Christian ^a,d   Matthias, Patrick ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

B cell development; Cell cycle control; Histone deacetylases; p21; p57

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1C; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; MESSENGER RNA; PROTEIN P21; PROTEIN P57; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION; WILD TYPE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; G1 PHASE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; MICE; MUTATION; S PHASE; UP-REGULATION;

MUS;

EID: 77649115437     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.552310     Document Type: Article

References (43)

1. Ahuja D, Saenz-Robles MT, Pipas JM. 2005. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24: 7729-7745.
2. Allfrey VG, Faulkner R, Mirsky AE. 1964. Acetylation and methylation of histones and their possible role in the regulation of Rna synthesis. Proc Natl Acad Sci 51: 786-794.
3. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et al. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734.
4. Berger SL. 2007. The complex language of chromatin regulation during transcription. Nature 447: 407-412.
5. Besson A, Dowdy SF, Roberts JM. 2008. CDK inhibitors: Cell cycle regulators and beyond. Dev Cell 14: 159-169.
6. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, et al. 2009. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459: 55-60.
7. Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN. 2009. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci 106: 7751-7755.
8. Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R, Reth M. 2006. Testing gene function early in the B cell lineage in mb1-cremice. Proc Natl Acad Sci 103: 13789-13794.
9. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
10. Hunter T, Pines J. 1994. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582.
11. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D. 1999. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: Comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res 27: 4324-4327.
12. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP. 2005. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601-607.
13. Kurdistani SK, Robyr D, Tavazoie S, Grunstein M. 2002. Genome-wide binding map of the histone deacetylase Rpd3 in yeast. Nat Genet 31: 248-254.
14. Kurdistani SK, Tavazoie S, Grunstein M. 2004. Mapping global histone acetylation patterns to gene expression. Cell 117: 721-733.
15. Kwon K, Hutter C, Sun Q, Bilic I, Cobaleda C, Malin S, Busslinger M. 2008. Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity 28: 751-762.
16. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, et al. 2002. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672-2681.
17. Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, et al. 2003. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 23: 2669-2679.
18. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. 2008. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 68: 2375-2383.
19. Luo J, Su F, Chen D, Shiloh A, Gu W. 2000. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
20. Malumbres M, Ortega S, Barbacid M. 2000. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol Chem 381: 827-838.
21. Matthias P, Rolink AG. 2005. Transcriptional networks in developing and mature B cells. Nat Rev Immunol 5: 497-508.
22. McHeyzer-Williams LJ, McHeyzer-Williams MG. 2005. Antigenspecific memory B cell development. Annu Rev Immunol 23: 487-513.
23. Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
24. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN. 2007. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes & Dev 21: 1790-1802.
25. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN. 2009. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc Natl Acad Sci 106: 7876-7881.
26. Roh TY, Cuddapah S, Zhao K. 2005. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes & Dev 19: 542-552.
27. Rolink A, Haasner D, Nishikawa S, Melchers F. 1993. Changes in frequencies of clonable pre B cells during life in different lymphoid organs of mice. Blood 81: 2290-2300.
28. Rountree MR, Bachman KE, Baylin SB. 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25: 269-277.
29. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, et al. 2007. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27: 4784-4795.
30. Soussi T, Wiman KG. 2007. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 12: 303-312.
31. Taplick J, Kurtev V, Kroboth K, Posch M, Lechner T, Seiser C. 2001. Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. J Mol Biol 308: 27-38.
32. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, et al. 2007. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3b activity. Nat Med 13: 324-331.
33. Vogelauer M, Wu J, Suka N, Grunstein M. 2000. Global histone acetylation and deacetylation in yeast. Nature 408: 495-498.
34. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. 2009. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138: 1019-1031.
35. Weiss RH. 2003. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4: 425-429.
36. Weston SA, Parish CR. 1990. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Methods 133: 87-97.
37. Yang XJ, Seto E. 2008. The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9: 206-218.
38. Zambetti GP. 2007. The p53 mutation 'gradient effect' and its clinical implications. J Cell Physiol 213: 370-373.
39. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, Matthias P. 2003. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22: 1168-1179.
40. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, et al. 2008. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28: 1688-1701.
41. Zimmermann S, Kiefer F, Prudenziati M, Spiller C, Hansen J, Floss T, Wurst W, Minucci S, Gottlicher M. 2007. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 67: 9047-9054.
42. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, Egger G, Grausenburger R, Schweifer N, Chiocca S, Decker T, et al. 2006. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 26: 7913-7928.
43. Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G, Lagger S, et al. 2009. The cyclin dependent kinase inhibitor p21 is a crucial target for Histone deacetylase 1 as regulator of cellular proliferation. Mol Cell Biol. doi: 10.1128/MCB.01500-09.